According to the present invention, it is possible to efficiently remove 13-dihydroepi-daunorubicin and 4-epi-feudomycin, which are typical impurities possibly contained in 4-epi-daunorubicin as a starting material, by using an organic acid salt of 4-epi-daunorubicin or a hydrate or solvate thereof as a novel production intermediate, thus making it possible to produce high-purity epirubicin.

According to the present invention, it is possible to efficiently remove 13-dihydroepi-daunorubicin and 4-epi-feudomycin, which are typical impurities possibly contained in 4-epi-daunorubicin as a starting material, by using an organic acid salt of 4-epi-daunorubicin or a hydrate or solvate thereof as a novel production intermediate, thus making it possible to produce high-purity epirubicin.

The present disclosure is generally directed to neuroactive substituted cyclopent[a]anthracenes as referenced herein, and pharmaceutically acceptable salts thereof, for use as, for example, an anesthetic, and/or in the treatment of disorders relating to GABA function and activity. The present disclosure is further directed to pharmaceutical compositions comprising such compounds.

The present disclosure is generally directed to neuroactive substituted cyclopent[a]anthracenes as referenced herein, and pharmaceutically acceptable salts thereof, for use as, for example, an anesthetic, and/or in the treatment of disorders relating to GABA function and activity. The present disclosure is further directed to pharmaceutical compositions comprising such compounds.

Provided are a precursor compound of a tetracyclic hydrocarbon and a preparation method thereof, and a tetracyclic hydrocarbon and a preparation method and use thereof. The precursor compound of the tetracyclic hydrocarbon with a structure shown in formula I has a polycyclic structure. The precursor compound is subjected to hydrodeoxygenation so as to be prepared into the tetracyclic hydrocarbon with a structure shown in formula II that has a high density (0.986 g/cm.sup.3), a high calorific value (41.14 MJ/L), and a low freezing point (less than ?60? C.).

##STR00001##

Provided are a precursor compound of a tetracyclic hydrocarbon and a preparation method thereof, and a tetracyclic hydrocarbon and a preparation method and use thereof. The precursor compound of the tetracyclic hydrocarbon with a structure shown in formula I has a polycyclic structure. The precursor compound is subjected to hydrodeoxygenation so as to be prepared into the tetracyclic hydrocarbon with a structure shown in formula II that has a high density (0.986 g/cm.sup.3), a high calorific value (41.14 MJ/L), and a low freezing point (less than ?60? C.).

##STR00001##

According to the present invention, it is possible to efficiently remove 13-dihydroepi-daunorubicin and 4-epi-feudomycin, which are typical impurities possibly contained in 4-epi-daunorubicin as a starting material, by using an organic acid salt of 4-epi-daunorubicin or a hydrate or solvate thereof as a novel production intermediate, thus making it possible to produce high-purity epirubicin.

According to the present invention, it is possible to efficiently remove 13-dihydroepi-daunorubicin and 4-epi-feudomycin, which are typical impurities possibly contained in 4-epi-daunorubicin as a starting material, by using an organic acid salt of 4-epi-daunorubicin or a hydrate or solvate thereof as a novel production intermediate, thus making it possible to produce high-purity epirubicin.

The present disclosure is generally directed to neuroactive substituted cyclopent[a]anthracenes as referenced herein, and pharmaceutically acceptable salts thereof, for use as, for example, an anesthetic, and/or in the treatment of disorders relating to GABA function and activity. The present disclosure is further directed to pharmaceutical compositions comprising such compounds.

The present disclosure is generally directed to neuroactive substituted cyclopent[a]anthracenes as referenced herein, and pharmaceutically acceptable salts thereof, for use as, for example, an anesthetic, and/or in the treatment of disorders relating to GABA function and activity. The present disclosure is further directed to pharmaceutical compositions comprising such compounds.